Cellular Biomedicine Group Inc. (CBMG) Given a $18.00 Price Target by Maxim Group Analysts
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) has been given a $18.00 price objective by equities research analysts at Maxim Group in a report released on Tuesday. The firm presently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 34.33% from the company’s current price.
Shares of Cellular Biomedicine Group (NASDAQ:CBMG) opened at 13.40 on Tuesday. The stock’s market cap is $190.96 million. Cellular Biomedicine Group has a one year low of $10.44 and a one year high of $24.42. The stock’s 50 day moving average price is $13.29 and its 200 day moving average price is $14.06.
WARNING: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/12/01/cellular-biomedicine-group-inc-cbmg-given-a-18-00-price-target-by-maxim-group-analysts.html.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Receive News & Stock Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related stocks with our FREE daily email newsletter.